Most doctors treat uACR as a routine kidney test. The data tells a different story. This biomarker may be one of the clearest windows into vascular aging we have — and risk starts rising long before anything looks "abnormal."

For decades the Women’s Health Initiative shaped how we view hormone therapy. The HRT timing hypothesis explained why benefits appear in younger menopausal women but not later. Emerging research suggests estrogen may protect cardiovascular health by preserving the endothelial glycocalyx, supporting arterial resilience and preventing early vascular damage before it becomes irreversible.

Plasmalogens are clearly depleted in aging and Alzheimer’s—but whether that depletion drives disease or reflects downstream dysfunction remains unresolved. This piece argues for a balanced, evidence-based middle ground: acknowledge biological plausibility and early biochemical signals, reject overstated clinical claims, and integrate emerging interventions cautiously within a framework of vascular optimization, transparency, and disciplined scientific curiosity.

The endothelial glycocalyx is a fragile sugar rich layer that lines blood vessels and may be one of the earliest drivers of vascular aging. Long before plaques form or blood pressure rises, damage to this protective surface can impair nitric oxide signaling, increase arterial stiffness, and amplify inflammation. Understanding and supporting glycocalyx health may offer a more upstream approach to preventing cardiovascular disease.

A new paper reframes hormone replacement therapy (HRT) not as symptom control, but as a potential geroprotective intervention capable of shaping the biology of aging in women. By positioning ovarian endocrine decline as an early, system-wide driver of aging—and emphasizing the importance of timing—it moves menopause medicine closer to geroscience. Yet it stops short of a true longevity-first model, revealing both meaningful progress and the limits of the current paradigm.

At the Global Longevity Summit in Geneva, I shared a panel with glycan biology pioneer Gordon Lauc and returned convinced we’re entering a new frontier in longevity medicine. Beyond estimating biological age like epigenetic clocks, glycan diagnostics reveal immune-driven inflammation and predict chronic disease risk years before symptoms appear. By decoding IgG glycosylation, we gain actionable insight into aging—and how to slow it.